Medical Marijuana and Opioids (MEMO) Study: protocol of a longitudinal cohort study to examine if medical cannabis reduces opioid use among adults with chronic pain.

摘要: Introduction In the USA, opioid analgesic use and overdoses have increased dramatically. One rapidly expanding strategy to manage chronic pain in context of this epidemic is medical cannabis. Cannabis has effects, but it also potential adverse effects. Further, its impact on not well studied. Managing people living with HIV particularly challenging, given high prevalence cannabis use. This study’s overarching goal understand how affects use, attention Δ9-tetrahydrocannabinol cannabidiol content, outcomes events. Methods analyses We are conducting a cohort study 250 adults without infection (a) severe or pain, (b) current (c) who newly certified for New York. Over 18 months, we collect data via in-person visits every 3 months web-based questionnaires 2 weeks. Data sources include: questionnaires; medical, pharmacy Prescription Monitoring Program records; urine blood samples; physical function tests. Using marginal structural models comparisons within participants’ 2-week time periods (unit analysis), will examine (primary exposure) (1) outcome), (2) (HIV viral load, CD4 count, antiretroviral adherence, risk behaviours) (3) events (cannabis disorder, illicit drug diversion, overdose/deaths, accidents/injuries, acute care utilisation). Ethics dissemination approved by Montefiore Medical Center/Albert Einstein College Medicine institutional review board. Findings be disseminated through conferences, peer-reviewed publications meetings stakeholders. Trial registration number ClinicalTrials.gov Registry (NCT03268551); Pre-results.